StockData

Alvotech vs Immunocore

ALVO and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALVO and IMCR compare

Alvotech grew revenue faster over the last twelve months (19.7% versus 13.1% for Immunocore).

Immunocore scores higher on the StockData Score (7 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALVOIMCR
Size and price
Market cap–$1.5B
Share price$4.19$29.94
Change, 1 year−25.2%−15.2%
Change, 5 years−57.8%−21.4%
Beta (5Y)0.430.69
Employees1,000524
StockData Score
Total score37 (better)
Valuation score01 (better)
Growth score22
Performance score03 (better)
Health score11
Dividend score00
Valuation
P/S–3.6×
P/B–3.7×
FCF yield–−1.2%
Fair value–$31.07
Margin of safety–3.6%
Growth
Revenue growth (TTM)19.7% (better)13.1%
Revenue growth, 5Y average54.5%–
Profitability
Gross margin59.8%98.9% (better)
Operating margin13.3% (better)−6.8%
Net margin–−7.5%
FCF margin−19.6%−4.2% (better)
Return on equity–−7.9%
Financial health
Net debt / EBITDA10.02–
Interest coverage0.5× (better)−2.4×
Current ratio1.654.62 (better)
Altman Z-score–1.45
Piotroski F-score–3
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield–0.00%
Ownership
Held by institutions–102%
Held by insiders67.7%15.5%
Insider net buying, 12 months–−$1.9M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.